These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39681395)

  • 1. Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Kijima T; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Katayama Y; Nishioka N; Morimoto K; Iwasaku M; Tokuda S; Shimose T; Takayama K
    Oncoimmunology; 2025 Dec; 14(1):2442116. PubMed ID: 39681395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
    Tachibana Y; Morimoto K; Yamada T; Kawachi H; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Katayama Y; Nishioka N; Iwasaku M; Tokuda S; Kijima T; Takayama K
    Invest New Drugs; 2024 Oct; 42(5):538-546. PubMed ID: 39168900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study.
    Masuda T; Tsubata Y; Hata K; Horie M; Kiura K; Kanaji N; Inoue T; Kodani M; Yanai M; Yamaguchi K; Matsumoto N; Yamasaki M; Ishikawa N; Masuda K; Takigawa N; Kuyama S; Kubota T; Nishii K; Hotta K; Hattori N
    Thorac Cancer; 2024 Dec; 15(34):2408-2417. PubMed ID: 39415454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study.
    Liguori L; Giorgio G; Polcaro G; Pagliara V; Malandrino D; Perri F; Cascella M; Ottaiano A; Conti V; Servetto A; Bianco R; Pepe S; Sabbatino F
    Front Immunol; 2024; 15():1419544. PubMed ID: 39664396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
    Tanaka H; Makiguchi T; Tozuka T; Kawashima Y; Oba T; Tsugitomi R; Koyama J; Tambo Y; Ogusu S; Saiki M; Gyotoku H; Hasegawa T; Miyauchi E; Sonoda T; Saito R; Nakatomi K; Sakatani T; Kudo K; Tsuchiya-Kawano Y; Nishio M
    Eur J Cancer; 2024 Dec; 213():115117. PubMed ID: 39522333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer.
    Vince M; Naqvi SMH; Pellini B; Verbosky M; Melzer D
    Lung Cancer; 2024 Dec; 198():107999. PubMed ID: 39500124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases.
    Ding K; Liu D; Jin X; Xu Y
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113391. PubMed ID: 39427497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab for Advanced Non-Small-Cell Lung Cancer With Concomitant Cachexia: An Observational Study.
    Du Y; Liu XY; Pan RL; Zhang XT; Si XY; Chen MJ; Wang MZ; Zhang L
    J Cachexia Sarcopenia Muscle; 2024 Dec; 15(6):2815-2825. PubMed ID: 39523982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study.
    Trestini I; Belluomini L; Dodi A; Sposito M; Caldart A; Kadrija D; Pasqualin L; Riva ST; Scaglione IM; Tregnago D; Avancini A; Insolda J; Confortini L; Casali M; Menis J; Vita E; Cintoni M; Todesco M; Milanese G; Sperduti I; D'Onofrio M; Infante M; Tiseo M; Mele MC; Tortora G; Milella M; Bria E; Pilotto S
    J Cachexia Sarcopenia Muscle; 2024 Dec; 15(6):2349-2360. PubMed ID: 39439222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).
    Aokage K; Koyama S; Kumagai S; Nomura K; Shimada Y; Yoh K; Wakabayashi M; Fukutani M; Furuya H; Miyoshi T; Tane K; Samejima J; Taki T; Hayashi T; Matsubayashi J; Ishii G; Nishikawa H; Ikeda N; Tsuboi M
    Clin Cancer Res; 2024 Dec; 30(24):5584-5592. PubMed ID: 39453771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.
    Miura K; Shukuya T; Furuya N; Morita R; Kisohara A; Mouri A; Watanabe S; Tanaka H; Hirata A; Hakozaki T; Hamai K; Matsumoto N; Watanabe K; Ashinuma H; Miyauchi E; Sugano K; Hosokawa S; Amano K; Morita S; Kobayashi K; Maemonodo M; Takahashi K
    J Cachexia Sarcopenia Muscle; 2024 Dec; 15(6):2618-2628. PubMed ID: 39351653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC).
    Landre T; Chouaïd C; Sadaoui N; Bouharati D; Taleb C
    J Chemother; 2024 Dec; 36(8):675-681. PubMed ID: 38303601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial.
    Liu SL; Li XY; Yang JH; Wen DX; Guo SS; Liu LT; Li YF; Luo MJ; Xie SY; Liang YJ; Sun XS; Yang ZC; Lv XF; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Sun R; Yang Q; Lan KQ; Jia GD; Li R; Zhao C; Xu RH; Chen QY; Tang LQ; Mai HQ
    Lancet Oncol; 2024 Dec; 25(12):1563-1575. PubMed ID: 39522541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC.
    Li H; Liu J; Zhang L; Xu Y; Wang X; Lan S; Cui P; Wang G; Cai S; Cheng Y
    J Immunother Cancer; 2024 Nov; 12(11):. PubMed ID: 39615893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
    Rha SY; Oh DY; Yañez P; Bai Y; Ryu MH; Lee J; Rivera F; Alves GV; Garrido M; Shiu KK; Fernández MG; Li J; Lowery MA; Çil T; Cruz FM; Qin S; Luo S; Pan H; Wainberg ZA; Yin L; Bordia S; Bhagia P; Wyrwicz LS;
    Lancet Oncol; 2023 Nov; 24(11):1181-1195. PubMed ID: 37875143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.